Genelabs Technologies Details
Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late-stage drug candidate for Hepatitis E partnered with GlaxoSmithKline, the company is advancing multiple partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus, targeting the HCV viral proteins - NS5B polymerase, NS4B, and NS5A. In January 2009 Genelabs was bought by GlaxoSmithKline.
Employees:
51 - 200
HQ:
["886-2-2655-7678","888-670-8900","(650) 369-9500","(650) 562-1519","( 02)2655-7572","0800-231914","(800) 356- 9526","+1 (212) 520-2765","6505621519","+1 650 562 1427","(650) 574-7990","908-547-2200"," 0065 67750008","(02)26557678","+971 56 285 0946","886-2- 26557678","(608) 274-4330","+44 777 598 8981","+1 201 724 6600","+0032-1658-9045","4-1-216/111/301","(800) 966-6632","650-369-9500","(415) 562- 1448","1159/000024978","1-650-369-9500","+886 2 2653 4401","408-924-2525)","(04) 22633813","+1-650-562-1424","02-2655-7678","(02)2655-7678","(4021) 212 2369","( 650 ) 369-9500","(301) 986-7922","+61 3 8379 0100","(650) 369-9500 ","0800-094380"]
Location:
, ,
Revenue: